Form 4: Adverum Biotechnologies' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Rabia Gurses Ozden, Chief Medical Officer of Adverum Biotechnologies, reports acquisition of stock options and restricted stock units.

Summary

• Rabia Gurses Ozden, the Chief Medical Officer of Adverum Biotechnologies, filed a Form 4 disclosing changes in beneficial ownership.
• On February 25, 2025, Ozden acquired 8,125 shares of Common Stock through the settlement of restricted stock units (RSUs).
• Ozden also acquired options to purchase 48,750 shares of Common Stock at an exercise price of $4.20, expiring on February 24, 2035.
• The RSUs vest in equal installments on each anniversary of March 1, 2025, over three years.
• The stock options vest 25% one year after March 1, 2025, and then 1/48th monthly thereafter, fully vesting in four years, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, indicating stability and alignment of interests.

Positives

• The grant of stock options and RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedules incentivize continued service with the company.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a commitment to long-term value creation at Adverum Biotechnologies.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Sangamo Therapeutics and CRISPR Therapeutics also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules are typical, aligning with industry norms to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the grants as a positive sign of incentivizing management to improve company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Adverum Biotechnologies, ADVM, Ozden, Chief Medical Officer